GBI Research's latest report, ""Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets"" assesses developments within the key elements of market access such as Health Economics and Outcome Research (HEOR), Health Technology Assessment (HTA) as well as pricing and reimbursements strategies for pharmaceutical products. This new report also discusses the need to integrate market access strategies earlier into the drug development process, in order to save time and costs related to conducting additional studies to prove the added benefits of a product. Additionally, our new study analyses the role of HTAs in market access and alternatives that could be used in cases where there is limited evidence. Detailed analysis of pricing and reimbursement policies in North America, five key European countries and Japan are also included in this report along with a myriad of relevant case studies. In order to gain optimum market access, companies have to analyze the economic benefit of the treatment, the level of competition and the required reimbursement support.
Payers continue to play an important role in market access. Products are increasingly being rejected for reimbursement, adversely affecting the market share of these products.
HEOR plays a critical part in market access
HTA has gained importance in reimbursement decisions
Pricing and reimbursement are the key elements of market access
Reasons to buy
This report will allow you to -
Table of Content
Health Economic and Outcomes Research (HEOR)
A Systemic Value Development Plan for HEOR
Types of Economic Evaluations
Overview of Cost-Effectiveness Analysis
Quality-Adjusted Life Year in HEOR
Pharmacoeconomic Modelling Methods
Health Technology Assessment (HTA) in Market Access
Key Benefits of HTA
Process and Dimensions of HTA
Principle HTA Regulatory Agencies
Risk Sharing Agreements When Limited Evidence is Available for HTA
Pricing and Reimbursement
Factors Affecting Pricing Decision
Pricing of a New Drug
Pharmaceutical Pricing Policies in the US
Impact Of Affordable Care Act on Market Access
Pharmaceutical Pricing and Reimbursement Policies in Canada
Pharmaceutical Pricing and Reimbursement Policies in Europe (UK, Germany, France, Italy and Spain)
Parallel Trade in Europe
Pharmaceutical Pricing and Reimbursement Policies in Japan
Economic Analysis Alongside Clinical Trials
Harmonization of Drug Approval and Marketing for Effective Market Access
Key Challenges for Achieving Optimum Market Access
Make an enquiry before buying this Report
Please fill the enquiry form below.
Delirium is a serious mental disorder, which can cause two most common type of behaviors, namely, hyperactive behavior, which is characterized by severe confusion, disorientation and disturbance in consciousness that fluctuates and hypoactive behavior, which is characterized by the sudden onset of withdrawal from interaction with the outside world. This serious mental disorder is mainly caused due to physical or mental illnesses, which is tempora...
Active pharmaceutical ingredients (APIs) are also referred as ‘bulk pharmaceuticals’ and they are the base of the pharmaceutical industry. APIs are used in the manufacture of various pharmaceutical and drug products, intended to yield the desired pharmacological effect. APIs are produced through various processes such as chemical synthesis, fermentation process, isolation etc. Active pharmaceutical ingredient contract manufacturing ma...
Enzyme-Linked Immunosorbent Assay (ELISA) is a test performed to detect the presence of antibodies in a biological liquid sample. ELISA is used as quality control check in many industry and as a diagnostic tool in plant pathology and in medicine. Though the latest emerging technology i.e. themultiplex proteomic array platform is rapidly replacing the ELISA, its market continues to grow since it is being preferred as a secondary val...